2018 ECTRIMS/EAN多发性硬化药物治疗指南解读

Comments on 2018 ECTRIMS/EAN guideline for pharmacological treatment of multiple sclerosis

欧洲多发性硬化治疗和研究委员会(European Committee of Treatment and Research in Multiple Sclerosis,ECTRIMS)和欧洲神经病学学会(European Academy of Neurology,EAN)共同发布了最新的、基于证据的多发性硬化(multiple sclerosis,MS)药物治疗指南,以指导MS患者药物治疗和医疗专业人员治疗决策。指南对成人MS和临床孤立综合征(clinically isolated syndrome,CIS)患者的药物修饰治疗(disease-modifying treatment,DMT)提出20条建议,内容涵盖了治疗有效性、治疗反应监测、治疗反应不充分的治疗策略、停止和更换治疗策略以及特殊情况下(如妊娠患者)的药物治疗。本文对该指南要点进行介绍,并予以解读。

The European Committee of Treatment and Research in Multiple Sclerosis(ECTRIMS) and the European Academy of Neurology(EAN) have joined to develop an up-to-date and evidence-based clinical practice guideline for the pharmacological treatment of people with multiple sclerosis(MS) to guide healthcare professionals in the decision-making process. This guideline focuses on disease-modifying treatment(DMT) for the adult patients with confirmed MS and clinically isolated syndrome(CIS) and a total of 20 recommendations have been agreed, encompassing treatment efficacy, monitoring of treatment response, strategies for inadequate treatment response, treatment discontinuation and/or switch, as well as treatment in special situations(such as pregnancy). This paper presents the highlights of the guideline and gives some comments.